Neuro Pace Inc NPCE
We take great care to ensure that the data presented and summarized in this overview for NeuroPace Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NPCE
View all-
Kck Ltd. Tortola, D85.27MShares$75 Million78.74% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.41MShares$48.5 Million1.03% of portfolio
-
Morgan Stanley New York, NY2.49MShares$35.5 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.43MShares$34.6 Million1.9% of portfolio
-
Kent Lake Pr LLC Anasco, PR1.48MShares$21.1 Million7.02% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.14MShares$16.3 Million3.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.06MShares$15 Million0.0% of portfolio
-
Black Rock Inc. New York, NY671KShares$9.55 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny643KShares$9.15 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY593KShares$8.43 Million0.09% of portfolio
Latest Institutional Activity in NPCE
Top Purchases
Top Sells
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Insider Transactions at NPCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2025
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,270,845
-100.0%
|
$47,437,605
$9.4 P/Share
|
|
Jan 30
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
200
-0.23%
|
$3,000
$15.0 P/Share
|
|
Jan 29
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
100
-0.11%
|
$1,500
$15.0 P/Share
|
|
Jan 24
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,200
-3.55%
|
$48,000
$15.01 P/Share
|
|
Oct 25
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
223,991
-4.08%
|
$1,119,955
$5.45 P/Share
|
|
Oct 23
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
147
-0.0%
|
$882
$6.02 P/Share
|
|
Oct 22
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,082
-0.07%
|
$24,492
$6.09 P/Share
|
|
Oct 21
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,720
-0.07%
|
$22,320
$6.1 P/Share
|
|
Oct 18
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,878
-0.09%
|
$29,268
$6.29 P/Share
|
|
Oct 17
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,294
-0.06%
|
$19,764
$6.28 P/Share
|
|
Oct 16
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,900
-0.13%
|
$41,400
$6.57 P/Share
|
|
Oct 15
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,017
-0.07%
|
$24,102
$6.5 P/Share
|
|
Oct 14
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,031
-0.07%
|
$24,186
$6.54 P/Share
|
|
Oct 11
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,572
-0.05%
|
$15,432
$6.35 P/Share
|
|
Oct 10
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,504
-0.05%
|
$15,024
$6.12 P/Share
|
|
Oct 09
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,123
-0.06%
|
$18,738
$6.1 P/Share
|
|
Oct 08
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,000
-0.11%
|
$36,000
$6.43 P/Share
|
|
Oct 07
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,910
-0.09%
|
$29,460
$6.66 P/Share
|
|
Oct 04
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,757
-0.1%
|
$34,542
$6.92 P/Share
|
|
Oct 03
2024
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,318
-0.06%
|
$19,908
$6.97 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 77.5K shares |
|---|
| Open market or private sale | 6.19M shares |
|---|